Topics
Researcher Tanaka and Ogawa from Pharmacology BU to Present at a symposium hosted by CIEM
2025.09.11
Our researcher, Hiroshi Tanaka and Masahiro Ogawa from the Pharmacology Business Unit, will give an oral presentation at at a symposium hosted by CIEM, to be held from September 24 , 2025, in Kanazawa city, Ishikawa prefecture, Japan.
If you plan to attend the symposium, we encourage you to join the session and hear the presentation.
Symposium Title:New Approaches in Anti-Tumor Drug Development
Date & Time: Wednesday, September 24, 2025, 13:30 – 17:40 (JST) (Doors open at 13:00)
Presentation Time: 14:50 – 15:50 (JST)
Location: Hotel Kanazawa, 2nd Floor Diamond Room (1-minute walk from Kanazawa Station East Exit)
Title:
1. Drug Discovery Support Strategies through Integrated Use of Preclinical Models with High Clinical Translatability
2. Development of a Humanized Mouse Platform for Various Modalities
Presenter: Hiroshi Tanaka, Pharmacology Business Unit & Masahiro Ogawa, Ph.D Pharmacology Business Unit
Presentation Summary
Highly human-extrapolatable in vitro and in vivo preclinical models play a critical role in the development of safe and effective new therapeutics. Among these, immune-humanized mouse models have attracted considerable attention as they enable accurate recapitulation of human immune responses, drug efficacy, and safety in a murine setting.
At the same time, conventional animal studies are facing increasing global attention due to ethical concerns, and regulatory agencies across countries are actively promoting the adoption of non-animal methodologies (NAMs).
In response to these trends, our company is advancing the development of an integrated drug discovery platform that incorporates both in vitro and in vivo models with high human relevance.
In our presentation, we will first provide an overview of our efforts utilizing fresh human cancer samples, patient-derived organoids, and microphysiological systems (MPS). We will then highlight the features and practical applications of our immune-humanized mouse platform, showcasing its value in translational research.
Axcelead DDP’s Soulution
Axcelead DDP provides highly translatable preclinical models centered around fresh human tumor samples and humanized mouse models. If you are facing challenges in bridging preclinical findings to human outcomes in drug discovery, we encourage you to consult with us.
Hiroshi Tanaka, Pharmacology Business Unit
After completing Master’s degree from the Graduate School of Agriculture, Kyushu University, he worked as a researcher at Takeda Pharmaceutical Company. He transitioned to Axcelead Drug Discovery Partners, Inc. and is currently engaged in pharmacological research, primarily in the field of oncology.
Masahiro Ogawa, Ph.D, Pharmacology Business Unit
After completing a Ph.D. in Medical Sciences at Osaka University Graduate School of Medicine, he worked as a university faculty member and a corporate researcher before joining Axcelead Drug Discovery Partners, Inc. in 2021. He is currently engaged in pharmacological research, primarily in the field of cancer immunology.